Alliance for Pandemic Preparedness

March 31, 2021

Efficacy of ChAdOx1 NCoV-19 (AZD1222) Vaccine against SARS-CoV-2 Variant of Concern 202012/01 (B.1.1.7): An Exploratory Analysis of a Randomised Controlled Trial

Category:

Topic:

Keywords (Tags):

  • Post-hoc analysis of the Oxford-AstraZeneca vaccine indicated that clinical vaccine efficacy against symptomatic, PCR-positive infection was 70.4% for the B.1.1.7 variant and 81.5% for non-B.1.1.7 lineages (not including the B.1.351 variant). Neutralization activity via vaccine-induced antibodies in vitro was also lower against the B.1.1.7 variant (geometric mean ratio 8.9). Participants 18 and older in efficacy cohorts (n=8534) were included in the analysis, and received either the COVID-19 vaccine or a control meningococcal conjugate vaccine. [EDITORIAL NOTE: This paper was summarized as a pre-print on February 5, 2021]

Emary et al. (Mar 30, 2021). Efficacy of ChAdOx1 NCoV-19 (AZD1222) Vaccine against SARS-CoV-2 Variant of Concern 202012/01 (B.1.1.7): An Exploratory Analysis of a Randomised Controlled Trial. The Lancet. https://doi.org/10.1016/S0140-6736(21)00628-0